PepGen(US:PEPG) Prnewswireยท2025-08-05 12:45Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1] Group 1: Allegations - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was less effective and safe than previously stated by the defendants [2] - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval purposes [2] - The lawsuit suggests that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [2] - Defendants' public statements were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]